231 related articles for article (PubMed ID: 1649570)
1. Characterization of high-level quinolone resistance in Campylobacter jejuni.
Gootz TD; Martin BA
Antimicrob Agents Chemother; 1991 May; 35(5):840-5. PubMed ID: 1649570
[TBL] [Abstract][Full Text] [Related]
2. Impact of mutations in DNA gyrase genes on quinolone resistance in Campylobacter jejuni.
Changkwanyeun R; Yamaguchi T; Kongsoi S; Changkaew K; Yokoyama K; Kim H; Suthienkul O; Usui M; Tamura Y; Nakajima C; Suzuki Y
Drug Test Anal; 2016 Oct; 8(10):1071-1076. PubMed ID: 26857529
[TBL] [Abstract][Full Text] [Related]
3. High-level quinolone resistance in clinical isolates of Campylobacter jejuni.
Segreti J; Gootz TD; Goodman LJ; Parkhurst GW; Quinn JP; Martin BA; Trenholme GM
J Infect Dis; 1992 Apr; 165(4):667-70. PubMed ID: 1313069
[TBL] [Abstract][Full Text] [Related]
4. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of ciprofloxacin and sparfloxacin on DNA gyrase purified from fluoroquinolone-resistant strains of methicillin-resistant Staphylococcus aureus.
Okuda J; Okamoto S; Takahata M; Nishino T
Antimicrob Agents Chemother; 1991 Nov; 35(11):2288-93. PubMed ID: 1666495
[TBL] [Abstract][Full Text] [Related]
6. Single or double mutational alterations of gyrA associated with fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli.
Bachoual R; Ouabdesselam S; Mory F; Lascols C; Soussy CJ; Tankovic J
Microb Drug Resist; 2001; 7(3):257-61. PubMed ID: 11759087
[TBL] [Abstract][Full Text] [Related]
7. In vivo selection of Campylobacter isolates with high levels of fluoroquinolone resistance associated with gyrA mutations and the function of the CmeABC efflux pump.
Luo N; Sahin O; Lin J; Michel LO; Zhang Q
Antimicrob Agents Chemother; 2003 Jan; 47(1):390-4. PubMed ID: 12499221
[TBL] [Abstract][Full Text] [Related]
8. Resistance to quinolones in Campylobacter jejuni and Campylobacter coli from Danish broilers at farm level.
Pedersen K; Wedderkopp A
J Appl Microbiol; 2003; 94(1):111-9. PubMed ID: 12492931
[TBL] [Abstract][Full Text] [Related]
9. Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations.
Wang Y; Huang WM; Taylor DE
Antimicrob Agents Chemother; 1993 Mar; 37(3):457-63. PubMed ID: 8384814
[TBL] [Abstract][Full Text] [Related]
10. Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.
Fisher LM; Lawrence JM; Josty IC; Hopewell R; Margerrison EE; Cullen ME
Am J Med; 1989 Nov; 87(5A):2S-8S. PubMed ID: 2574005
[TBL] [Abstract][Full Text] [Related]
11. Purification of Citrobacter freundii DNA gyrase and inhibition by quinolones.
Aoyama H; Sato K; Fujii T; Fujimaki K; Inoue M; Mitsuhashi S
Antimicrob Agents Chemother; 1988 Jan; 32(1):104-9. PubMed ID: 2831810
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Campylobacter jejuni DNA gyrase as the target of quinolones.
Changkwanyeun R; Usui M; Kongsoi S; Yokoyama K; Kim H; Suthienkul O; Changkaew K; Nakajima C; Tamura Y; Suzuki Y
J Infect Chemother; 2015 Aug; 21(8):604-9. PubMed ID: 26096494
[TBL] [Abstract][Full Text] [Related]
13. Patterns of quinolone susceptibility in Campylobacter jejuni associated with different gyrA mutations.
McIver C; Hogan T; White P; Tapsall J
Pathology; 2004 Apr; 36(2):166-9. PubMed ID: 15203753
[TBL] [Abstract][Full Text] [Related]
14. Increased resistance to quinolones in Campylobacter jejuni: a genetic analysis of gyrA gene mutations in quinolone-resistant clinical isolates.
Ruiz J; Goñi P; Marco F; Gallardo F; Mirelis B; Jimenez De Anta T; Vila J
Microbiol Immunol; 1998; 42(3):223-6. PubMed ID: 9580533
[TBL] [Abstract][Full Text] [Related]
15. Antibacterial activity of a new tetracyclic quinolone, No. 5290, against norfloxacin- and ciprofloxacin-resistant strains of Staphylococcus aureus.
Kotera Y; Inoue Y; Ohashi M; Ito K; Tsukamoto G
Chem Pharm Bull (Tokyo); 1991 Oct; 39(10):2644-6. PubMed ID: 1666861
[TBL] [Abstract][Full Text] [Related]
16. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.
Kocagöz T; Hackbarth CJ; Unsal I; Rosenberg EY; Nikaido H; Chambers HF
Antimicrob Agents Chemother; 1996 Aug; 40(8):1768-74. PubMed ID: 8843279
[TBL] [Abstract][Full Text] [Related]
17. Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa.
Kitamura A; Hoshino K; Kimura Y; Hayakawa I; Sato K
Antimicrob Agents Chemother; 1995 Jul; 39(7):1467-71. PubMed ID: 7492087
[TBL] [Abstract][Full Text] [Related]
18. The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones.
Thomson KS; Sanders CC
J Antimicrob Chemother; 1998 Aug; 42(2):179-87. PubMed ID: 9738835
[TBL] [Abstract][Full Text] [Related]
19. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. Investigation Team.
Smith KE; Besser JM; Hedberg CW; Leano FT; Bender JB; Wicklund JH; Johnson BP; Moore KA; Osterholm MT
N Engl J Med; 1999 May; 340(20):1525-32. PubMed ID: 10332013
[TBL] [Abstract][Full Text] [Related]
20. Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase.
Alovero FL; Pan XS; Morris JE; Manzo RH; Fisher LM
Antimicrob Agents Chemother; 2000 Feb; 44(2):320-5. PubMed ID: 10639357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
